表紙：抗血栓薬の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、適応症別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

市場調査レポート

商品コード

1789232

抗血栓薬の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、適応症別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Antithrombotic Drugs Market Size, Share, and Growth Analysis, By Type (Apixaban, Debigatran), By Drug Class, By Indication, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年08月07日
発行: SkyQuest
ページ情報: 英文 176 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 787,898円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 921,692円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,055,486円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.66円

全表示
概要
目次

概要

サンプル依頼リストに入れる

抗血栓薬の世界市場規模は2023年に484億米ドルと評価され、2024年の522億2,000万米ドルから2032年には959億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは7.9%で成長する見通しです。

抗血栓薬の世界市場は、特に心血管疾患の有病率の増加、高齢者人口の拡大、新規経口抗凝固薬（NOACs）の需要の高まりなど、いくつかの有力な要因によって推進されています。心房細動や静脈血栓塞栓症などの心血管疾患は、世界の健康上の課題であり、これらの薬剤に対する大きな需要を牽引しています。さらに、高齢者層はますます血栓性疾患に罹患しやすくなっており、患者層はさらに広がっています。ダビガトランやリバーロキサバンなどのNOACは、その利便性と相互作用や出血のリスクの低さから支持を集めています。さらに、予防ヘルスケアに対する意識の高まりが、より大きな普及を促しています。しかし、出血のリスク、薬価の高さ、規制の厳しさといった課題は、市場の成長を妨げる可能性があります。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

F. Hoffmann-La Roche Ltd.（Switzerland）
Teva Pharmaceutical Industries Ltd.（Ireland）
Sanofi（France）
Pfizer Inc.（U.S.）
GlaxoSmithKline plc（U.K.）
Novartis AG（Switzerland）
Merck & Co., Inc.（U.S.）
Allergan（Ireland）
AstraZeneca（U.K.）
Johnson & Johnson Private Limited（U.S.）
Hikma Pharmaceuticals PLC（U.K.）
Fresenius Kabi AG（Germany）
Eisai Co., Ltd.（Japan）
Bristol-Myers Squibb Company（U.S.）
Bayer AG（Germany）
DAIICHI SANKYO COMPANY, LIMITED（Japan）

結論と提言

Product Code: SQMIG35I2432

Global Antithrombotic Drugs Market size was valued at USD 48.4 billion in 2023 and is poised to grow from USD 52.22 billion in 2024 to USD 95.95 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

The global market for antithrombotic drugs is being propelled by several influential factors, particularly the growing prevalence of cardiovascular diseases, an expanding geriatric population, and a heightened demand for novel oral anticoagulants (NOACs). Cardiovascular issues, including atrial fibrillation and venous thromboembolism, represent a leading global health challenge, driving significant demand for these medications. Moreover, the elderly demographic is increasingly susceptible to thrombotic disorders, further widening the patient pool. NOACs, such as dabigatran and rivaroxaban, are gaining traction for their convenience and lower risk of interactions and bleeding. Additionally, rising awareness regarding preventive healthcare is fostering greater adoption. However, challenges such as the risk of bleeding, the high cost of medications, and stringent regulatory hurdles could hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antithrombotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antithrombotic Drugs Market Segments Analysis

Global Antithrombotic Drugs Market is segmented by Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin and Rivaroxaban. Based on Drug Class, the market is segmented into Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants and Others. Based on Indication, the market is segmented into Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE) and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antithrombotic Drugs Market

The increasing incidence of cardiovascular conditions such as atrial fibrillation, deep vein thrombosis, and strokes has significantly boosted the demand for antithrombotic medications. Contributing factors include a rising population, sedentary lifestyles, and the prevalence of metabolic syndrome, all of which underscore the importance of anticoagulants and antiplatelet agents. These medications are essential not only for immediate treatment but also for the long-term management of cardiovascular risks. As awareness of these health issues grows and preventive measures become more vital, the antithrombotic drugs market is expected to expand further, catering to the urgent need for effective therapeutic solutions.

Restraints in the Global Antithrombotic Drugs Market

The Global Antithrombotic Drugs market faces significant limitations due to the increased risk of bleeding associated with these medications, particularly in elderly individuals or those with additional health conditions. This elevated risk complicates clinical decision-making and often necessitates continuous monitoring, adjustments in dosage, or even the cessation of treatment. Such safety concerns can diminish physicians' confidence and affect patient adherence, ultimately impacting overall market penetration and the long-term success of therapy. As a result, healthcare providers must carefully weigh the benefits and drawbacks, which may hinder the widespread adoption of antithrombotic treatments in various patient populations.

Market Trends of the Global Antithrombotic Drugs Market

The global antithrombotic drugs market is witnessing a notable trend towards next-generation targeted therapies that prioritize ultra-specificity in targeting coagulation factors. This innovative approach aims to minimize bleeding risks while maintaining sustained efficacy, catering to the urgent demand for safer treatment options. By precisely addressing pathological processes, these advanced therapies promise to enhance safety profiles compared to existing medications, facilitating personalized treatment strategies that effectively balance clot prevention with bleeding control. As healthcare professionals increasingly seek tailored solutions for patients, the adoption of these cutting-edge antithrombotic therapies is expected to drive market growth and transformation in patient care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis

Global Antithrombotic Drugs Market Size by Type & CAGR (2025-2032)

Market Overview
Apixaban
Debigatran
Edoxaban
Fondaparinux
Heparin
Rivaroxaban

Global Antithrombotic Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Thrombolytic Drugs
Anti-Platelet Drugs
Anticoagulants
Others

Global Antithrombotic Drugs Market Size by Indication & CAGR (2025-2032)

Market Overview
Atrial Fibrillation
Stroke
Deep vein thrombosis (DVT)
Pulmonary Embolism (PE)
Others

Global Antithrombotic Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable
Others

Global Antithrombotic Drugs Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Antithrombotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Antithrombotic Drugs Market Size & CAGR (2025-2032)

North America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
- US
- Canada
Europe (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Private Limited (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

抗血栓薬の市場規模、シェア、成長分析、タイプ別、薬剤クラス別、適応症別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Antithrombotic Drugs Market Size, Share, and Growth Analysis, By Type (Apixaban, Debigatran), By Drug Class, By Indication, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

抗血栓薬市場規模：タイプ別& CAGR（2025-2032）

抗血栓薬市場規模：薬剤クラス別& CAGR（2025-2032）

抗血栓薬市場規模：適応症別& CAGR（2025-2032）

抗血栓薬市場規模：投与経路別& CAGR（2025-2032）

抗血栓薬市場規模：エンドユーザー別& CAGR（2025-2032）

抗血栓薬市場規模：流通チャネル別& CAGR（2025-2032）

抗血栓薬市場規模：地域別& CAGR（2025-2032）